

2018 Essential Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Essential Hypertension Market

<https://marketpublishers.com/r/276B84FB193EN.html>

Date: June 2018

Pages: 70

Price: US\$ 999.00 (Single User License)

ID: 276B84FB193EN

Abstracts

2018 Essential Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Essential Hypertension Market is a comprehensive report on Essential Hypertension market.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Essential Hypertension pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Essential Hypertension pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Essential Hypertension pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES

1.2 List of Tables

2 ESSENTIAL HYPERTENSION PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Essential Hypertension Pipeline Snapshot

2.3 Essential Hypertension Pipeline by Phase

2.4 Essential Hypertension Pipeline by Company

2.5 Essential Hypertension Pipeline by Mechanism of Action

3 ESSENTIAL HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS

Actelion Ltd

Bayer AG

Beijing CoSci Med-Tech Co.,Ltd

Boryung Pharmaceutical Co., Ltd

Chong Kun Dang Pharmaceutical Corp.

Daiichi Sankyo Company, Limited

HanAll Biopharma Co., Ltd.

Hypogen, Inc.

Il Dong Pharmaceutical Co Ltd

Merck KGaA

Novartis International AG

Quantum Genomics SA

RMJ Holdings, LLC

Shin Poong Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited

Theracos, Inc.

Yuhan Co, Ltd.

4 ESSENTIAL HYPERTENSION R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ESSENTIAL HYPERTENSION PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Essential Hypertension Pipeline by Phase, H2- 2018

Figure 2: Essential Hypertension Pipeline by Companies, H2- 2018

Figure 3: Company Wise Pipeline Drug Phases, H2- 2018

Figure 4: Essential Hypertension Pipeline by Mechanism of Action, H2- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Essential Hypertension Pipeline by Phase, H2- 2018

Essential Hypertension Pipeline by Companies, H2- 2018

Essential Hypertension Pipeline by Mechanism of Action, H2- 2018

Table 1: Actelion Ltd Essential Hypertension Pipeline Drugs, H2- 2018

Table 2: Bayer AG Essential Hypertension Pipeline Drugs, H2- 2018

Table 3: Beijing CoSci Med-Tech Co.,Ltd Essential Hypertension Pipeline Drugs, H2- 2018

Table 4: Boryung Pharmaceutical Co., Ltd Essential Hypertension Pipeline Drugs, H2- 2018

Table 5: Chong Kun Dang Pharmaceutical Corp. Essential Hypertension Pipeline Drugs, H2- 2018

Table 6: Daiichi Sankyo Company, Limited Essential Hypertension Pipeline Drugs, H2- 2018

Table 7: HanAll Biopharma Co., Ltd. Essential Hypertension Pipeline Drugs, H2- 2018

Table 8: Hypogen, Inc. Essential Hypertension Pipeline Drugs, H2- 2018

Table 9: Il Dong Pharmaceutical Co Ltd Essential Hypertension Pipeline Drugs, H2- 2018

Table 10: Merck KGaA Essential Hypertension Pipeline Drugs, H2- 2018

Table 11: Novartis International AG Essential Hypertension Pipeline Drugs, H2- 2018

Table 12: Quantum Genomics SA Essential Hypertension Pipeline Drugs, H2- 2018

Table 13: RMJ Holdings, LLC Essential Hypertension Pipeline Drugs, H2- 2018

Table 14: Shin Poong Pharmaceutical Co Ltd Essential Hypertension Pipeline Drugs, H2- 2018

Table 15: Takeda Pharmaceutical Company Limited Essential Hypertension Pipeline Drugs, H2- 2018

Table 16: Theracos, Inc. Essential Hypertension Pipeline Drugs, H2- 2018

Table 17: Yuhan Co, Ltd. Essential Hypertension Pipeline Drugs, H2- 2018

I would like to order

Product name: 2018 Essential Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Essential Hypertension Market

Product link: <https://marketpublishers.com/r/276B84FB193EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/276B84FB193EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

